Research Progress in Androgen Receptor and Triple Negative Breast Cancer / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 303-310, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-981268
ABSTRACT
The research on androgen receptor (AR) in breast cancer is advancing.Although the prognostic value of AR in triple negative breast cancer (TNBC) is controversial,a variety of studies have demonstrated that the lack of AR expression exacerbates disease progression.Moreover,the TNBC subtype of AR(-) is more aggressive than that of AR(+) due to the lack of prognostic biomarkers and therapeutic targets.With the discovery and deepening research of novel therapeutic targets such as phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin and S-phase kinase-associated protein 2 signaling pathways,as well as the emerging of immunotherapies,the treatment options for TNBC are increasing.Regarding the role of AR in TNBC,the studies about the tumor biology of AR(-)TNBC and novel biomarkers for improved management of the disease remain insufficient.In this review,we summarize the research progress of AR in TNBC,put forward avenues for future research on TNBC,and propose potential biomarkers and therapeutic strategies that warrant investigation.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Biomarkers
/
Signal Transduction
/
Receptors, Androgen
/
Triple Negative Breast Neoplasms
Limits:
Humans
Language:
Chinese
Journal:
Acta Academiae Medicinae Sinicae
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS